Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the battle against age-related conditions, by improving its safety profile and reducing development costs.

BALTIMORE, March 07, 2024 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc.(Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions, today announced that Telomir, alongside its partner Frontage Laboratories, presented a scientific poster at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 with data showing the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells (HUVEC), and mesenchymal stem cells (MSC). The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.

Danielle R. Baker, Ph.D., of Frontage Laboratories, presented the poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” at the conference, which took place in Singapore, on February 29th and March 1st. The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.

“We are honored that this poster was accepted for presentation at the NUHS Conference. Moreover, the promising data we presented at the NUHS Conference showed the advances we are making at potentially treating age-related conditions and prolonging human life,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir. “If Telomir-1 can safely extend telomeres in people, it could vastly alter the aging process and redefine our potential for living longer, healthier lives. We are excited at what the future holds and we look forward to presenting additional data to the longevity community in the coming months.”

Dr. Michael Roizen, special advisor to Telomir, added, “While more research is needed, these preliminary findings open up the possibility that many diseases long considered inevitable consequences of aging could become avoidable. This study further demonstrates our belief that Telomir-1 may have the effect of reversing age through telomere regeneration, enabling the production of more stem cells, essentially allowing an individual to repair oneself.”

The conference was orchestrated by the NUHS Centre for Healthy Longevity, a distinguished entity devoted to extending healthy life by delaying aging, prolonging disease-free life, and maintaining high functionality. Through rigorous research and strategic implementations, the NUHS Centre strives to unveil and promote innovative geroprotective interventions. The CHL Conference 2024 serves as a hallmark event, reflecting the NUHS Centre’s steadfast commitment to fostering a collaborative environment, facilitating discourse, and propelling the field of healthy longevity forward.

As part of its ongoing work on Telomir-1, the Company collaborated with InSilicoTrials, an innovator in leveraging AI and simulations to enhance drug development, to perform advanced AI modeling on Telomir-1. Early research has confirmed the mechanism of action of Telomir-1 and suggests that it may be a potent metal inhibitor, potentially leading to a reversal of aging through telomere regeneration. The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.

Comments are closed.
Start simulating now